2
|
Hishinuma E, Narita Y, Rico EMG, Ueda A, Obuchi K, Tanaka Y, Saito S, Tadaka S, Kinoshita K, Maekawa M, Mano N, Nakayoshi T, Oda A, Hirasawa N, Hiratsuka M. Functional Characterization of 12 Dihydropyrimidinase Allelic Variants in Japanese Individuals for the Prediction of 5-Fluorouracil Treatment-Related Toxicity. Drug Metab Dispos 2023; 51:165-173. [PMID: 36414408 DOI: 10.1124/dmd.122.001045] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2022] [Revised: 10/11/2022] [Accepted: 10/27/2022] [Indexed: 11/23/2022] Open
Abstract
The drug 5-fluorouracil (5-FU) is the first-choice chemotherapeutic agent against advanced-stage cancers. However, 10% to 30% of treated patients experience grade 3 to 4 toxicity. The deficiency of dihydropyrimidinase (DHPase), which catalyzes the second step of the 5-FU degradation pathway, is correlated with the risk of developing toxicity. Thus, genetic polymorphisms within DPYS, the DHPase-encoding gene, could potentially serve as predictors of severe 5-FU-related toxicity. We identified 12 novel DPYS variants in 3554 Japanese individuals, but the effects of these mutations on function remain unknown. In the current study, we performed in vitro enzymatic analyses of the 12 newly identified DHPase variants. Dihydrouracil or dihydro-5-FU hydrolytic ring-opening kinetic parameters, Km and Vmax , and intrinsic clearance (CLint = Vmax /Km ) of the wild-type DHPase and eight variants were measured. Five of these variants (R118Q, H295R, T418I, Y448H, and T513A) showed significantly reduced CLint compared with that in the wild-type. The parameters for the remaining four variants (V59F, D81H, T136M, and R490H) could not be determined as dihydrouracil and dihydro-5-FU hydrolytic ring-opening activity was undetectable. We also determined DHPase variant protein stability using cycloheximide and bortezomib. The mechanism underlying the observed changes in the kinetic parameters was clarified using blue-native polyacrylamide gel electrophoresis and three-dimensional structural modeling. The results suggested that the decrease or loss of DHPase enzymatic activity was due to reduced stability and oligomerization of DHPase variant proteins. Our findings support the use of DPYS polymorphisms as novel pharmacogenomic markers for predicting severe 5-FU-related toxicity in the Japanese population. SIGNIFICANCE STATEMENT: DHPase contributes to the degradation of 5-fluorouracil, and genetic polymorphisms that cause decreased activity of DHPase can cause severe toxicity. In this study, we performed functional analysis of 12 DHPase variants in the Japanese population and identified 9 genetic polymorphisms that cause reduced DHPase function. In addition, we found that the ability to oligomerize and the conformation of the active site are important for the enzymatic activity of DHPase.
Collapse
Affiliation(s)
- Eiji Hishinuma
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Yoko Narita
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Evelyn Marie Gutiérrez Rico
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Akiko Ueda
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Kai Obuchi
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Yoshikazu Tanaka
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Sakae Saito
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Shu Tadaka
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Kengo Kinoshita
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Masamitsu Maekawa
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Nariyasu Mano
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Tomoki Nakayoshi
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Akifumi Oda
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Noriyasu Hirasawa
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| | - Masahiro Hiratsuka
- Advanced Research Center for Innovations in Next-Generation Medicine (E.H., A.U., Y.T., S.S., K.K., M.M., N.H., M.H.), Laboratory of Pharmacotherapy of Life-Style Related Diseases, Graduate School of Pharmaceutical Sciences (Y.N., E.M.G.R., K.O., N.H., M.H.), Tohoku Medical Megabank Organization (E.H., S.S., S.T., K.K., M.H.), Graduate School of Life Sciences (Y.T.), and Graduate School of Information Sciences (K.K.), Tohoku University, Sendai, Japan; Department of Pharmaceutical Sciences, Tohoku University Hospital, Sendai, Japan (M.M., N.M., N.H., M.H.); Department of Biophysical Chemistry, Faculty of Pharmacy, Meijo University, Nagoya Japan (T.N., A.O.); and Graduate School of Information Sciences, Hiroshima City University, Hiroshima, Japan (T.N.)
| |
Collapse
|